CD30 Antibody

NSJ Bioreagents
Product Code: NSJ-V3703IHC
Product Group: Primary Antibodies
Supplier: NSJ Bioreagents
CodeSizePrice
NSJ-V3703IHC-7ML7 ml£534.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG1 kappa
Antibody Clonality: Recombinant Antibody
Antibody Clone: rKi-1/779
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Store the recombinant CD30 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Images

1 / 2
IHC testing of FFPE human Hodgkin's lymphoma with recombinant CD30 antibody (clone rKi-1/779). Required HIER: boil tissue sections in 10mM Tris with 1mM EDTA, pH 9, for 10-20 min followed by cooling at RT for 20 min.~
2 / 2
SDS-PAGE analysis o

IHC testing of FFPE human Hodgkin's lymphoma with recombinant CD30 antibody (clone rKi-1/779). Required HIER: boil tissue sections in 10mM Tris with 1mM EDTA, pH 9, for 10-20 min followed by cooling at RT for 20 min.~
SDS-PAGE analysis o

Documents

Further Information

Application Details:
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Application Note:
Optimal dilution of the recombinant CD30 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Description:
Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the CD30/Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
Format:
Purified
Formulation:
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*
Immunogen:
Recombinant full length human protein was used as the immunogen for the recombinant CD30 antibody.
Limitation:
This recombinant CD30 antibody is available for research use only.
Localization:
Cell surface, cytoplasmic
Purity:
Protein G affinity chromatography
Uniprot #:
P28908